Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of “Buy” by Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $17.6667.

AMRX has been the subject of a number of recent research reports. Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. The Goldman Sachs Group reiterated a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. UBS Group boosted their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Barclays increased their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Finally, Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 29th.

Amneal Pharmaceuticals Trading Down 2.2%

Shares of Amneal Pharmaceuticals stock opened at $17.27 on Friday. The firm has a 50-day moving average of $17.15 and a 200-day moving average of $14.56. The stock has a market cap of $5.51 billion, a PE ratio of 35.24 and a beta of 1.27. Amneal Pharmaceuticals has a 52-week low of $9.15 and a 52-week high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Insiders Place Their Bets

In other news, EVP Jason B. Daly sold 210,000 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the transaction, the executive vice president owned 253,390 shares in the company, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 363,016 shares of company stock valued at $6,334,567. Corporate insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $26,000. Federated Hermes Inc. boosted its position in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after acquiring an additional 2,168 shares in the last quarter. Transamerica Financial Advisors LLC increased its stake in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares during the last quarter. Comerica Bank increased its stake in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the last quarter. Finally, Strs Ohio acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $52,000. 31.82% of the stock is owned by institutional investors.

Key Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Amneal entered the second half of 2026 with higher guidance and a broader product pipeline, supporting the company’s growth outlook. However, erosion of its Rytary product remains a concern. Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
• Positive Sentiment: The Kashiv transaction gives Amneal an integrated biosimilars platform that could become a significant long-term growth engine, expanding its pipeline and commercial opportunities. Integration, regulatory execution and product adoption are key hurdles. Can Amneal’s Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
• Neutral Sentiment: Brokerages have a consensus price target of $17.67, indicating limited potential upside relative to recent trading levels and suggesting analysts see a fairly balanced risk-reward profile. Amneal Pharmaceuticals Receives $17.67 Consensus Price Target
• Neutral Sentiment: AMRX has rallied 44.8% over three months, but the advance now faces tests from upcoming earnings, new product launches and pipeline progress. Its higher valuation and Rytary revenue erosion could limit further gains. AMRX Stock Surges 44.8% in 3 Months
• Negative Sentiment: Amneal executives disclosed sizable stock sales. EVP Jason B. Daly sold 210,000 shares for approximately $3.65 million and an additional 6,613 shares, while EVP Nikita Shah sold 146,403 shares for approximately $2.56 million. The transactions substantially reduced their ownership stakes and may be weighing on investor sentiment, although insider sales do not necessarily indicate deteriorating fundamentals. Amneal Executive Stock Sale Filings

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.